Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01868516 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
A Phase 2 study, sponsored by Targacept.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,635
- Enrollment target
NCT01868516 is a Phase 2 study that has completed, run by Targacept. The registered enrollment target is 1,635 participants.
The verdict
NCT01868516, a Phase 2 study, has completed, sponsored by Targacept.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,635 participants
- Enrollment target
Study Summary
Overactive bladder (OAB) is a syndrome characterized by symptoms of a sudden need to urinate with or without incontinence (leaking). The purpose of this study is to test whether dexmecamylamine is safe and effective compared to placebo for the treatment of symptoms of OAB.
Interventions
- DRUG Placebo
- DRUG dexmecamylamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,635 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01868516
The ClinicalTrials.gov registry entry for NCT01868516 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,635 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Targacept, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01868516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01868516 about?
NCT01868516 is a clinical study titled "Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder". Overactive bladder (OAB) is a syndrome characterized by symptoms of a sudden need to urinate with or without incontinence (leaking). The purpose of this study is to test whether dexmecamylamine is safe and effective compared to placebo for the treatment of symptoms of OAB.
What is the current status of trial NCT01868516?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,635 participants. The study started on 2013-05. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01868516?
The interventions under investigation include: Placebo (DRUG), dexmecamylamine (DRUG).
Who is sponsoring clinical trial NCT01868516?
This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.